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INTroDuCTIoN
Non-small cell lung cancer (NSCLC) is still a main contrib-
utor to the global cancer mortality burden.1 A total of 
234,030 new cases are estimated to occur in 2018 only in 
the USA.2 While for most malignancies a steady increase 
of survival was seen in recent years this is almost not the 
case for lung cancers.3 In recent years, there were made 
advances concerning treatment of late staged NSCLC 
by targeting therapy against the driver mutations of this 
disease (e.g. EGFR, ALK, ROS) with specific immuno-
therapy.4,5 Nevertheless, tumor resection was proven to be 
highly effective and might allow for a curative result in early 
stages.6 Imaging plays a key role for the exact evaluation of 
local tumor extension (T-stage) and assessment of local and 
distant spread.7 Especially 18F-fluodeoxyglucose positron 
emission tomography (18F-FDG PET/CT) was proven to be 
an important tool for assessing lymph node (N) and distant 
metastasis (M) in patients with NSCLC8 and is therefore 
implemented in various international guidelines for presur-
gical evaluation.9
PET/MRI is a relatively new modality that came into clin-
ical use only a few years ago.10 While initially the use of MRI 
for chest imaging was perceived as a challenging topic,11 
recent studies indicated that PET/MRI in NSCLC might be 
non-inferior for early tumor stages12,13 and possibly even 
superior compared to PET/CT with regard to lesion conspi-
cuity and/or diagnostic confidence in advanced stages with 
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objective: The purpose of this study was to compare 
the diagnostic accuracy of positron emission tomog-
raphy (PET)/MRI with PET/CT for determining tumor 
resectability of non-small cell lung cancer (NSCLC).
Methods: Sequential trimodality PET/CT/MRI was 
performed in 36 patients referred with the clinical 
question of resectability assessment in NSCLC. PET/CT 
and PET/MR images including T1 weighted sequence 
(T1-Dixon) and respiration gated T2 weighted sequence 
(T2-Propeller) were evaluated for resectability-defining 
factors; i.e. longest diameter of the tumor, minimal 
tumor distance to the carina, mediastinal invasion, 
invasion of the carina, pleural infiltration, pericardial 
infiltration, diaphragm infiltration, presence of addi-
tional nodules.
results: There was no significant difference of maximal 
axial diameter measurements of the primary lung tumors 
and narrow limits of agreement in Bland–Altman analysis 
ranging from −11.1  mm to + 11.8  mm for T2-Propeller and 
from −14.3  mm to + 13.8  mm for T1-Dixon sequence. A 
high agreement of PET/MR with PET/CT for the different 
resectability-defining factors was observed (k from 
0.769 to 1.000). There was an excellent agreement of 
T2-Propeller sequence and CT for additional pulmonary 
nodule detection (k of 0.829 and 0.833), but only a 
moderate and good agreement using T1-Dixon sequence 
(k of 0.484 and 0.722).
Conclusion: In NSCLC the use of PET/MRI, including a 
dedicated pulmonary MR imaging protocol, provides a 
comparable diagnostic value for determination of tumor 
resectability compared to PET/CT.
advances in knowledge: Our findings suggest that 
whole body PET/MRI can safely be used for the 
local staging of NSCLC patients. Further studies are 
warranted to determine whether it is feasible to inte-
grate an imaging sequence in a whole body PET/MRI 
setting with the potential advantage of detection of liver 
or brain metastases.
2 of 9 birpublications.org/bjr Br J Radiol;91:20180379
BJR  Messerli et al
liver or bone lesions.14,15 Further, PET/MR might be beneficial 
for detecting brain metastases.16
Therefore, the purpose of the present study was to test whether 
18F-FDG PET/MRI, including a dedicated but short pulmonary 
MRI protocol, provides an equivalent diagnostic value for deter-
mining tumor resectability compared to the present standard of 
care with 18F-FDG PET/CT in NSCLC patients.
MeThoDS aND MaTerIalS
This study was performed in subjects enroled in a prospective 
single-center trial. Patients were acquired prospectively as part of 
a larger prospective study with several different subgroups. The 
study was approved by the local ethics committee and written 
informed consent was obtained from all study subjects prior to 
the examination.
Patients
A total of 45 consecutive adult patients (median age 64 years, 
range 39–85 years; 16 female and 29 male) referred for either 
staging (n = 34) or restaging/follow up (n = 11) of suspected 
or known NSCLC participated in this study. All patients were 
referred with the clinical question for resectability assessment. 
Inclusion criteria were (a) clinically indicated 18F-FDG PET/CT 
and (b) willingness to participate in an additional MRI exam-
ination. Exclusion criteria were (a) unwillingness to undergo 
an additional MRI examination, and (b) contraindications for 
MRI (e.g. claustrophobia, MR-incompatible implanted medical 
devices). Of the 45 patients initially included, 9 patients were 
subsequently excluded due to histological results other than 
NSCLC (small cell lung cancer, n = 3; metastases of cervical 
cancer, n = 1; neuroendocrine tumor, n = 1; inflammatory 
disease n = 1) or because no lung lesion was detected (n = 3). 
Finally, 36 patients were left for evaluation (median age 64, range 
44–85 years; 11 female and 25 male).
Imaging techniques
Imaging was performed on a sequential trimodality PET/CT/
MRI set-up. The system consists of a full-ring time-of-flight 
64-slice PET/CT scanner (Discovery PET/CT 690 VCT, GE 
Healthcare, Waukesha, WI) and a 3-Tesla (3T) MR scanner 
(Discovery MR 750w, GE Healthcare, Waukesha, WI), connected 
by a shuttle device that allows for sequential scanning without 
repositioning of the patient.17
The study patients fasted for at least 4 h before being injected 
with 250–380 MBq of 18F-FDG depending on the BMI. The 
total uptake time was set to 60 min. 35–40 min after injection, 
patients were positioned in the MR scanner. All MR images 
were acquired during this 20–25 min prior to PET/CT imaging. 
Whole-body multisection MRI was performed with an axial T1 
weighted three-dimensional dual-echo fast spoiled gradient echo 
sequence (Liver accelerated volume acquisition, LAVA-Flex). 
Water-only and fat-only images were automatically generated 
from the dual-echo acquisition using a Dixon-based method.18 
Further, a T2 weighted sequence with motion correction (peri-
odically rotated overlapping parallel lines with enhanced recon-
struction, PROPELLER) was acquired during free breathing with 
respiratory triggering.19 Details on MR acquisition parameters 
are given in Table 1 and were published previously.20 No contrast 
media was administered to the patients for the MR acquisition. 
Subsequently patients were transferred to the PET/CT, where 
standard, clinical image acquisition started immediately. The 
PET data sets covered the region from the vertex of the skull to 
the mid thighs. Low dose CT covering the same region as PET, 
used for attenuation correction purposes as well as for anatomic 
Table 1. Acquisition parameters of MRI pulse sequences
T2-Propeller T1-Dixon
Repetition time/echo time, ms* ~10000/100 4.3/1.6
Slice thickness, mm 4.5 4.0
Gap, % 2 0
Matrix 288 × 288 288 × 224
Field of view, mm 40 50
Bandwidth, kHz 62.5 142.86
Voxel size, mm3 1.4 × 1.4×4.5 1.7 × 2.2×2.0
Flip angle° NA 12
Acquisition time, min:s ~5 mina 00:14
aThe acquisition time of T2-Propeller depends on the breathing 
pattern of the patient.
Table 2. Imaging criteria for potential tumor resectability as assessed by the readers
Resectable Unresectable
Local tumor 
assessment
Tumor size Tumor <7 cm longest diameter Tumor >7 cm longest diameter
Distance to carina Tumor distance to carina >2 cm Tumor distance to carina <2 cm
Mediastinal infiltration No mediastinal infiltration Mediastinal infiltration
Pleural infiltration No pleural or only visceral pleural infiltration Parietal pleural infiltration
Pericardium infiltration Pericardium not infiltrated Pericardium infiltrated
Diaphragm infiltration No infiltration of the diaphragm Infiltration of the diaphragm
Infiltration of the brachial plexus Brachial plexus not infiltrated Brachial plexus infiltrated
Infiltration of the fissure / lobe No infiltration of the fissure and adjacent lobe Infiltration of the fissure and adjacent lobe
Lung nodules Additional lung nodules No additional nodules or only in ipsilateral lobes Separate nodules in a contralateral lobe
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localization of 18F-FDG uptake was acquired. Further, a regular 
dose CT scans of the chest was acquired in breath-hold as by 
clinical standard in patients referred for staging/restaging of lung 
cancer. After the acquisition of the PET data, 70 ml of intrave-
nous contrast (Visipaque 320, GE Healthcare, Waukesha, WI) 
were injected with a flow rate of 3 ml s−1. The CT scan was started 
60 s after initiating the contrast injection. Scan parameters were 
as follows: Tube voltage, 100 kV; tube current with automated 
dose modulation, 60–440 mA/slice; pitch 0.984:1; collimation 64 
× 0.625; rotation time, 0.5 s; coverage speed 78 mm/s; field of 
view 40 cm; images with a transverse pixel size of 0.625 mm and 
a slice thickness of 2.5 mm, reconstructed in the axial, sagittal 
and coronal plane with 1.25 mm. The entire PET/CT-MR acqui-
sition protocol imaging setup has been published several times 
for different research questions by our group before.21
Imaging processing and reading technique
Analyses of the acquired PET, CT and MR image data sets 
were carried out on a dedicated review workstation (Advan-
tage Workstation, v. 4.6, GE Healthcare, Waukesha, WI), which 
allows for viewing images of all modalities side-by-side and/or 
overlay mode (CT, PET as well as PET/CT and PET/MR). Only 
combined PET/CT images and PET/MR images were compared 
for this study as done before in other tri-modality studies from 
our group.21 For our study, the T1 weighted sequence water-only 
(i.e. LAVA-Flex in breath-hold, hereafter called T1-Dixon) and 
the respiration gated T2 weighted (i.e. Propeller, hereafter called 
T2-Propeller) were assessed.
Data analyses
Two radiologists (Ma.M. and T.F., with 5 and 14 years of expe-
rience in chest radiology) assessed anonymized image data sets 
in random order and blinded to all clinical information, except 
the fact of suspected or known presence of NSCLC. Both readers 
interpreted PET/CT images first, followed by PET/MR images 
with a delay of 6 weeks between the readings in order minimize 
the potential of recall bias. On PET/CT and PET/MRI, the readers 
assessed pre-defined factors concerning local tumor resectability. 
These factors included six findings determining T-classification of 
the tumor (i.e. mediastinal infiltration, visceral or parietal pleural 
infiltration, infiltration of the pericardium, infiltration of the 
diaphragm, infiltration of the brachial plexus, infiltration of the 
fissure/adjacent lobe), and another three criteria that are taken into 
consideration for local tumor stage assessment (longest diameter 
of the tumor, distance to carina, presence of additional nodules). 
The longest/maximal diameter of the tumor was measured in the 
axial plane where the largest tumor extent was seen in CT and 
MR For the measurement in CT lung window settings were used. 
Table 2 summarizes the imaging criteria to determine the resect-
ability as assessed by the readers and as previously suggested.22
Statistical analyses
All statistical analyses were performed using SPSS 23.0 (IBM 
Corporation, Armonk, NY) and MedCalc v. 15.8 (MedCalc 
Table 3. TNM-statusa of 36 patients
n (%)
T-Stage 
  T1 11 (31 %)
  T2 7 (19 %)
  T3 12 (33 %)
  T4 6 (17 %)
N-Stage 
  N0 12 (34 %)
  N1 8 (22 %)
  N2 9 (25 %)
  N3 7 (19 %)
M-Stage 
  M0 29 (81 %)
  M1 7 (19 %)
aFinal stages were assessed by histopathological (n = 19) and clinical 
(n = 17) follow-up.
Figure 1. Bland–Altman plot for measurement of tumor diameter in all patients (n = 36) in CT images and MR T2-Propeller images 
(A), and MR T1-Dixon (B) displaying the measurements of both readers. Bland-Altman limits of agreement were −11.1 to 11.8 mm 
comparing MR T2-Propeller with CT with a mean difference of +0.35 mm (A) and −14.3 to 13.8 mm comparing MR T1-Dixon with 
CT with a mean difference of −0.27 mm (B), both p > 0.05.
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Software, Ostend, Belgium). Categorical variables are expressed 
as proportions, and continuous variables are presented as mean 
± standard deviation or median (range) depending on the distri-
bution of values. A two-tailed p-value of <0.05 was considered to 
indicate significance for all statistical tests applied.
Comparison of tumor diameters and distance to the 
carina in CT and MR
To evaluate agreement of tumor measurements in CT and MR 
scans, differences of size were plotted against the mean diam-
eter using the Bland–Altman method. The limits of agreement 
were defined as the mean difference ±1.96 × standard deviation. 
Bland–Altman analyses including the measurements of both 
readers were performed (a) for primary lung tumors and (b) 
for tumor distance to the carina for all patients where primary 
tumor was localized >0 cm to <5 cm. Further, differences of 
tumor measurements and measurements of tumor distance to 
the carina among CT and MR were statistically compared using 
a one-sided t-test against zero.
Assessment of agreement of tumor distance to the 
Carina and resectability-defining factors
The agreement of whether a tumor was >2 cm from,>0–2 cm 
from, or abutting/invading the carina as well as all resectabil-
ity-defining factor between CT and MR sequences for both 
readers and the readers separately was determined using linear 
weighted kappa statistics, with 95% confidence intervals (CIs). 
The k values were interpreted as: poor (k < 0.20), fair (k = 0.21–
0.40), moderate (k = 0.41–0.60), good (k = 0.61–0.80), and excel-
lent (k = 0.81–1.00) agreement.23
Assessment of potential resectability
Based on local tumor extent of CT and MR, the potential resect-
ability of the NSCLC was defined, according the factors listed 
Table 4. Reader agreement of CT and MR images for resectability-defining factors for the study patients (n = 36)
PET/CT vs PET/MR T2 Propeller PET/CT vs PET/MR T2 Dixon
Overall Reader 1 Reader 2 Overall Reader 1 Reader 2
Local tumor 
assessmenta 
Mediastinal 
infiltration
0.968
(0.907–1.000)
0.936
(0.813–1.000)
1.000
(1.000–1.000)
0.968
(0.907–1.000)
0.936
(0.813–1.000)
1.000
(1.000–1.000)
Pleural 
infiltration
1.000
(1.000–1.000)
1.000
(1.000–1.000)
1.000
(1.000–1.000)
0.881
(0.783–0.979)
0.804
(0.638–0.970)
0.953
(0.862–1.000)
Diaphragm 
infiltration
1.000
(1.000–1.000)
1.000
(1.000–1.000)
1.000
(1.000–1.000)
1.000
(1.000–1.000)
1.000
(1.000–1.000)
1.000
(1.000–1.000)
Infiltration of 
the fissure/lobe
0.820
(0.683–0.957)
0.875
(0.707–1.000)
0.769
(0.562–0.977)
0.791
(0.645–0.937)
0.816
(0.618–1.000)
0.769
(0.562–0.977)
Lung nodules Additional lung nodules
0.829
(0.698–0.960)
0.822
(0.630–1.000)
0.833
(0.655–1.000)
0.618
(0.438–0.799)
0.484
(0.185–0.783)
0.722
(0.505–0.939)
kof pairwise comparisons overall as well as for both readers separately aredisplayed, 95% confidence interval inparenthesis.
aResults for pericardial infiltration (n = 0), and brachial plexus invasion (n = 0) are not shown in the table because of the low prevalence in the 
study patients.
Figure 2. BlandAltman plot for measurements of the distance of the tumor from the carina in CT images and MR T2-Propeller 
images (A), and MR T1-Dixon (B) in patients with tumors located <5 cm to the carina but without reaching the carina. Measure-
ments of both readers are displayed. Bland-Altman limits of agreement were −6.0 to 11.5 mm comparing MR T2-Propeller with CT 
with a mean difference of +2.8 mm (A), p < 0.05. Limits of agreement comparing MR T1-Dixon with CT were −8.6 to 12.2 mm with 
a mean difference of +1.8 mm (B), p > 0.05.
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in Table 2. A score of 1 was assigned if the PET/MR assessment 
revealed a resectable tumor and a score of 0 if the tumor was not 
resectable, with PET/CT serving as standard of reference.
reSulTS
The final TNM classification of the included 36 patients is 
presented in Table 3.
Assessment of tumor size in CT and MR
The mean tumor size was 36.5 ± 19.7 mm on CT, and 36.9 ± 
20.7 mm on PET/MR T2-Propeller and 36.3 ± 21.1 mm on T1-
Dixon, respectively. Bland–Altman analysis comparing PET/MR 
T2-Propeller with PET/CT revealed a mean difference of +0.3 
mm and limits of agreement from −11.1 to 11.8 mm, the mean 
difference thereby was not statistically different (p = 0.62). Simi-
larly, comparing PET/MR T1-Dixon with PET/CT we observed a 
mean difference of −0.3 mm and limits of agreement of −14.3 to 
13.8 mm, the mean difference was not statistically different (p = 
0.75). Bland-Altman plots are shown in Figure 1.
Measurement of distance to Carina in PET/CT and 
PET/MR
The mean distance of lung tumor to the carina was 22.2 ± 12.3 mm 
on CT, and 25.0 ± 13.7 mm on PET/MR T2-Propeller and 22.9 
± 14.1 mm on T1-Dixon, respectively. The Bland–Altman plots 
for measurements of the tumor distance to the carina are given 
in Figure 2. Bland–Altman analysis comparing PET/MR T2-Pro-
peller with PET/CT revealed a mean difference of +2.8 mm and 
limits of agreement from −6.0 to 11.5 mm, the mean difference 
thereby was statistically different (p = 0.01). Comparing PET/MR 
T1-Dixon with PET/CT, we observed a mean difference of +1.8 
Figure 3. Sankey plots illustrating ratings of resectability-defining factors comparing PET/MR sequences with CT including the 
ratings of both readers. PET, positron emission tomography.
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mm and limits of agreement from −8.6 to 12.2 mm, the mean 
difference was not statistically different (p = 0.16).
κ statistics showed a high agreement of T2-Propeller and CT 
images on whether the distance of the tumor was >2 cm from 
the carina,>0 – 2 cm from from the carina, or abutting/invading 
the carina for with a weighted kappa of 0.888 [95% CI (0.789–
0.987)]. There was also a high agreement of T1-Dixon and CT 
on the same subject with a weighted κ of 0.808 [95% CI (0.663 
– 0.953)], p < 0.001.
Diagnostic agreement of resectability-defining 
factors of PET/MR compared to PET/CT
There was generally a high agreement for most resectability-de-
fining factors, with mostly k-values indicating excellent agree-
ment. Detailed data including all k-values for the assessment of 
resectability-defining factors comparing CT and MR are given 
in Table 4.
Analysis for potential resectability
Differences of resectability-defining factors as assessed by MR 
and CT by both readers are presented in Figure  3. Of all 36 
subjects, 33 (92%) and 32 (89%) were correctly classified by 
T2-Propeller by Reader 1 and Reader 2 using CT as reference, 
respectively, Figure 4. Of all 36 subjects, 31 (86%) and 28 (78%) 
were correctly classified by T1-Dixon by Reader 1 and Reader 2 
using CT as reference, respectively, see Figure 4. Representative 
images of PET/CT and PET/MR are given in Figure 5.
DISCuSSIoN
This study sought to determine the accuracy of 18F-FDG PET/
MRI for assessing tumor resectability in NSCLC. We therefore 
prospectively included patients undergoing clinically indicated 
PET/CT for lung cancer resectability assessment and imaged 
them with MR using a respiration-gated T2 weighted sequence 
and three-dimensional dual-echo GRE pulse sequence in a 
trimodality PET/CT-MR setup. We found a high agreement of 
different resectability defining factors of PET/MR with PET/CT 
as reference among readers with different levels of experience.
PET/CT has proven to be a vital tool for a thorough assessment 
of patients with NSCLC because of the high spatial resolution 
of CT and the additional metabolic information derived by the 
18F-FDG PET for detection of lymph nodes and distant metas-
tasis.24–26 Optimal staging is particularly important in a presur-
gical stage to limit surgery or multimodality treatment to only 
those patients who might benefit from such a therapy and avoid 
potentially futile surgery, related morbidity as well as unneces-
sary costs.
When comparing PET/MR with the reference PET/CT we found 
no significant difference of maximal axial diameter measure-
ments of the primary lung tumors and narrow limits of agree-
ment in Bland–Altman analysis ranging from −11.1 mm to 
+11.8 mm for T2-Propeller and from −14.3 mm to +13.8 mm for 
T1-Dixon sequence, respectively. This is in line with a previous 
study that reported excellent agreement for estimation of the 
size of primary tumors in PET/MR.12 A reliable estimation of 
the maximal axial diameter of lung tumors in different imaging 
modalities is important, as this measure reflects the pathological 
T-stage.27 It has to be pointed out that our protocol was acquired 
without contrast media and with basically only two sequences. 
The reason for that was to test whether a fast and rather basic 
protocol for the lung is sufficient for diagnostic purposes since the 
MRI–component within a PET/MR is often very lengthy. Thus, 
in view of testing an MRI protocol for possible integration into 
a whole-body PET/MRI, only this limited protocol was chosen. 
We would also like to highlight that given the recent technical 
improvement of MR sequences we were able to perform respira-
tion-gated MR scans at reasonably low scanning times.
A previous study reported some source of bias owing to poten-
tial misinterpretation of main bronchus involvement in PET/
MR.28 In contradiction to that, we found an overall excellent 
agreement for the classification of tumor distance to the carina 
for T2-Propeller and T1-Dixon, respectively. Interestingly, there 
was a tendency for overestimating the tumor distance to carina 
in T2-Propeller sequence, however even though this was statis-
tically significant, this is most likely not clinically relevant with 
a mean difference (i.e. overestimation) of measurement of only 
+2.8 mm. Moreover, as stated before the agreement on whether a 
tumor was >2 cm from,>0–2 cm from, or abutting/invading the 
carina was excellent comparing T2-Propeller with CT.
Our study is one of the early evaluations to investigate the 
relevant resectability defining factors instead of comparing 
T-stages in simultaneous PET/CT and PET/MR. By doing 
that, we observed a good to excellent agreement of MR with 
CT for mediastinal infiltration, pleural infiltration, infiltration 
of diaphragm and adjacent lobe. Despite the aforementioned 
Figure 4. Sankey plots illustrating per patient analyses for 
lung tumor resectability comparing PET/MR sequences with 
CT including the ratings of both readers. PET, positron emis-
sion tomography.
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efforts and results, one of the concerns for substituting the CT 
component in PET/CT with the MR component in PET/MR is 
the lower accuracy or even described inability of MRI for the 
detection of small lung nodules.29–31 However, we observed an 
excellent agreement of T2-Propeller sequence with CT for nodule 
detection with κ values of 0.829 and 0.833 of the two readers, but 
only a moderate and good agreement using T1-Dixon sequence 
with a κ of 0.484 and 0.722 of the two readers. Previous reports 
also presented similar data with T2-Propeller yielding signifi-
cantly higher nodule detection rates than Dixon MR in onco-
logical patients, including a subanalysis for PET-positive as well 
as confirmed malignant nodules.32 Also in the latter categories, 
the T2-Propeller was not significantly inferior compared to CT 
from PET/CT. However, concerning overall detection rates of 
lung lesions, the MRI from PET/MR was still inferior compared 
to CT with significantly lower detection rates for small lesions. 
Thus, for staging purposes with known lung lesions, PET/MR 
might be safely used but it is certainly still not comparable to CT 
for smaller pulmonary lesions.
Additional improvements of MR sequences for lung imaging are 
on the horizon—with the most promising probably being short 
echo time imaging (e.g. ultra-short time to echo and zero time to 
echo—so called UTE- and ZTE-sequences). Recently, Ohno et 
al demonstrated improved pulmonary nodule detection rates of 
thin-section MRI with UTE and further described the usefulness 
of UTE for evaluation of nodule type as at least as efficacious as 
standard-dose thin-section CT.33 Other studies using UTE-se-
quences have shown a good visualization of the lung paren-
chyma and mediastinum in adult patients34,35 as well as a good 
visibility of the airways including the trachea and main bronchi 
in infants.36
There are several limitations that have to be considered in the 
present study. There are only a limited number of patients 
included in this study which is why our results must be regarded 
as initial results with the introduced sequences and any conclu-
sions drawn from the present analysis awaits further proof in 
bigger (ideally multicentric) observations. As a result of the low 
number of patients, we encountered a second limitation which 
includes the fact that not all primarily intended resectability 
defining factors occurred in the study group such as brachial 
plexus infiltration.
In conclusion, we found that PET/MRI, including a dedicated 
but short pulmonary MRI protocol, provides a comparable diag-
nostic value for determination of tumor resectability compared 
to PET/CT. Further studies are warranted to determine whether 
Figure 5. Representative images of a 62-year-old female that underwent sequential trimodality PET/CT/MRI referred for resect-
ability assessment of NSCLC. Coronal PET maximum-intensity-projection image (A) shows a focal FDG-active lesion in the left 
upper lobe (arrow). Axial CT image (B) shows a nodule in the left upper lobe and axial coregistered PET/CT image (C) confirms 
18F-FDG-activity of the lesion. MR and PET/MR images with T2-Propeller (D, E) as well as T1-Dixon (F, G). The readers inde-
pendently agreed on PET/CT as well as PET/MR on resectability of the tumor. The patient subsequently underwent lobectomy and 
final histopathological diagnosis confirmed adenocarcinoma. 18F-FDG, 18F-fluodeoxyglucose; NSCLC, non-small cell lung cancer; 
PET, positron emission tomography.
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